...
search icon
janx-img

Janux Therapeutics Inc, Common Stock

JANX

NMQ

$31.05

-$1.02

(-3.18%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.73B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
419.00K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
3.27
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$22.52 L
$71.71 H
$31.05

About Janux Therapeutics Inc, Common Stock

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameJANXSectorS&P500
1-Week Return5.97%3.64%6.36%
1-Month Return0.71%-5.42%-5.32%
3-Month Return-28.69%-6.89%-8.86%
6-Month Return-41.86%-7.54%-5.61%
1-Year Return-34.08%-1.81%8.61%
3-Year Return135.58%2.1%27.58%
5-Year Return23.46%35.25%90.38%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue380.00K3.64M8.61M8.08M10.59M[{"date":"2020-12-31","value":3.59,"profit":true},{"date":"2021-12-31","value":34.35,"profit":true},{"date":"2022-12-31","value":81.34,"profit":true},{"date":"2023-12-31","value":76.34,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue13.00K36.57M75.70M1.96M-[{"date":"2020-12-31","value":0.02,"profit":true},{"date":"2021-12-31","value":48.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.58,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(13.00K)3.64M8.61M6.13M10.59M[{"date":"2020-12-31","value":-0.12,"profit":false},{"date":"2021-12-31","value":34.35,"profit":true},{"date":"2022-12-31","value":81.34,"profit":true},{"date":"2023-12-31","value":57.88,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(3.42%)100.00%100.00%75.81%100.00%[{"date":"2020-12-31","value":-3.42,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":75.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses4.84M36.57M75.70M81.06M109.44M[{"date":"2020-12-31","value":4.43,"profit":true},{"date":"2021-12-31","value":33.41,"profit":true},{"date":"2022-12-31","value":69.18,"profit":true},{"date":"2023-12-31","value":74.07,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(4.84M)(32.93M)(67.09M)(72.98M)(98.85M)[{"date":"2020-12-31","value":-484300000,"profit":false},{"date":"2021-12-31","value":-3292900000,"profit":false},{"date":"2022-12-31","value":-6709100000,"profit":false},{"date":"2023-12-31","value":-7297900000,"profit":false},{"date":"2024-12-31","value":-9884700000,"profit":false}]
Total Non-Operating Income/Expense(2.15M)514.00K8.06M27.19M59.71M[{"date":"2020-12-31","value":-3.6,"profit":false},{"date":"2021-12-31","value":0.86,"profit":true},{"date":"2022-12-31","value":13.51,"profit":true},{"date":"2023-12-31","value":45.55,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(6.78M)(32.67M)(63.06M)(58.29M)(68.99M)[{"date":"2020-12-31","value":-678400000,"profit":false},{"date":"2021-12-31","value":-3267200000,"profit":false},{"date":"2022-12-31","value":-6305900000,"profit":false},{"date":"2023-12-31","value":-5829300000,"profit":false},{"date":"2024-12-31","value":-6899400000,"profit":false}]
Income Taxes(1.53M)(113.00K)(8.90M)1.79M-[{"date":"2020-12-31","value":-85.56,"profit":false},{"date":"2021-12-31","value":-6.32,"profit":false},{"date":"2022-12-31","value":-498.29,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(5.25M)(32.56M)(54.15M)(60.08M)-[{"date":"2020-12-31","value":-525500000,"profit":false},{"date":"2021-12-31","value":-3255900000,"profit":false},{"date":"2022-12-31","value":-5415400000,"profit":false},{"date":"2023-12-31","value":-6008010500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(6.78M)(32.67M)(63.06M)(62.60M)(68.99M)[{"date":"2020-12-31","value":-678400000,"profit":false},{"date":"2021-12-31","value":-3267200000,"profit":false},{"date":"2022-12-31","value":-6305900000,"profit":false},{"date":"2023-12-31","value":-6260000000,"profit":false},{"date":"2024-12-31","value":-6899400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(5.25M)(32.56M)(54.15M)(58.29M)(68.99M)[{"date":"2020-12-31","value":-525500000,"profit":false},{"date":"2021-12-31","value":-3255900000,"profit":false},{"date":"2022-12-31","value":-5415400000,"profit":false},{"date":"2023-12-31","value":-5829300000,"profit":false},{"date":"2024-12-31","value":-6899400000,"profit":false}]
EPS (Diluted)(2.63)(3.23)(1.52)(1.34)(1.28)[{"date":"2020-12-31","value":-263.31,"profit":false},{"date":"2021-12-31","value":-323,"profit":false},{"date":"2022-12-31","value":-152,"profit":false},{"date":"2023-12-31","value":-134,"profit":false},{"date":"2024-12-31","value":-128,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

JANX
Cash Ratio 58.72
Current Ratio 59.21

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

JANX
ROA (LTM) -8.57%
ROE (LTM) -10.09%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

JANX
Debt Ratio Lower is generally better. Negative is bad. 0.04
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.96

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

JANX
Trailing PE NM
Forward PE NM
P/S (TTM) 179.02
P/B 1.79
Price/FCF NM
EV/R 78.68
EV/Ebitda NM

FAQs

What is Janux Therapeutics Inc share price today?

Janux Therapeutics Inc (JANX) share price today is $31.05

Can Indians buy Janux Therapeutics Inc shares?

Yes, Indians can buy shares of Janux Therapeutics Inc (JANX) on Vested. To buy Janux Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in JANX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Janux Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Janux Therapeutics Inc (JANX) via the Vested app. You can start investing in Janux Therapeutics Inc (JANX) with a minimum investment of $1.

How to invest in Janux Therapeutics Inc shares from India?

You can invest in shares of Janux Therapeutics Inc (JANX) via Vested in three simple steps:

  • Click on Sign Up or Invest in JANX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Janux Therapeutics Inc shares
What is Janux Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Janux Therapeutics Inc (JANX) is $71.71. The 52-week low price of Janux Therapeutics Inc (JANX) is $22.52.

What is Janux Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Janux Therapeutics Inc (JANX) is 1.79

What is the Market Cap of Janux Therapeutics Inc?

The market capitalization of Janux Therapeutics Inc (JANX) is $1.73B

What is Janux Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Janux Therapeutics Inc is JANX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top